AUXL - AUXILIUM PHARMACEUTICALS INC
Form 10-K Period: DEC.31.11 Date Filed: FEB.29.12
Transcript Split
  
  
     
Move to First Section Move to Last Section
INDEX
Page-by-Page
  Form 10-K (Entire Filing)

Filing Body

Page 1: UNITED STATES

Page 2: AUXILIUM PHARMACEUTICALS, INC.

Page 3: This Report on Form 10-K (the Report ) contains forward-looking statements within the meaning of Sec

Page 4: PART I

Page 5: Phase III:

Page 6: Cost-effectiveness and convenience.

Page 7: Regulation

Page 8: Broad prescription coverage

Page 9: Frozen Shoulder Syndrome

Page 10: R D status

Page 11: STRATEGIC RELATIONSHIPS

Page 12: N/A

Page 13: License to Pfizer

Page 14: License to Asahi Kasei

Page 15: MANUFACTURING

Page 16: DEPENDENCE ON CERTAIN CUSTOMERS

Page 17: Other Delivery Options

Page 18: Future Delivery Options

Page 19: Other Competition

Page 20: N/A

Page 21: Regulation Outside of the U.S.

Page 22: Physician Self-Referral Laws

Page 23: Compliance Program

Page 24: N/A

Page 25: Testim

Page 26: Orphan Drug Status

Page 27: EMPLOYEES

Page 28: FINANCIAL INFORMATION

Page 29: In addition to the other information included in this Report, the following factors should be consid

Page 30: Inventories produced during a launch period may not be needed and could result in additional charges

Page 31: We make business decisions based on forecasts of future sales of our products and product candidates

Page 32: Testim competes in a very competitive market, and if we are unable to compete effectively with the o

Page 33: International commercialization of our products and our product candidates faces significant obstacl

Page 34: If we are unable to maintain regulatory approval for XIAFLEX, we may not have an alternate use for o

Page 35: Because we depend on third parties to conduct certain laboratory tests, clinical trials and other cr

Page 36: Our third-party manufacturers are subject to regulatory oversight, which may delay or disrupt our de

Page 37: We do not control the actions of our collaborators, and breaches of our agreements by any of them co

Page 38: We may not be able to license XIAFLEX for development and commercialization in the rest of the world

Page 39: N/A

Page 40: As a condition for approval of XIAFLEX for Dupuytren s, we are required to comply with post-marketin

Page 41: We may not be able to obtain or maintain orphan drug exclusivity for our products or product candida

Page 42: If clinical trials for our product candidates are delayed, we would be unable to commercialize our p

Page 43: Risks Related to Intellectual Property

Page 44: If we breach any of the agreements under which we license development or commercialization rights to

Page 45: If our products or our future products infringe the intellectual property of our competitors or othe

Page 46: We may have to engage in costly litigation to enforce or protect our proprietary technology or to de

Page 47: Risks Related to Compliance

Page 48: Our controls over external financial reporting may fail or be circumvented.

Page 49: Risks Related to Our Financial Results, Our Need for Additional Financing and Our Stock Price

Page 50: We may become subject to stockholder activism efforts that each could cause material disruption to o

Page 51: Malvern

Page 52: N/A

Page 53: PART II

Page 54: Issuer Purchases of Equity Securities

Page 55: Comparative Stock Performance Graph

Page 56: SELECTED CONSOLIDATED FINANCIAL DATA

Page 57: You should read the following discussion and analysis of our financial condition and results of oper

Page 58: Phase III:

Page 59: Phase I Clinical Trials

Page 60: Operational Highlights

Page 61: Testim

Page 62: Net revenues

Page 63: Cost of goods sold

Page 64: Research and development

Page 65: Selling, general and administrative

Page 66: XIAFLEX

Page 67: Interest income.

Page 68: XIAFLEX

Page 69: Sources and Uses of Cash

Page 70: Contractual Commitments

Page 71: Summary of Contractual Commitments

Page 72: Collaboration and out-license agreements-

Page 73: N/A

Page 74: Valuation of Equity Instruments used in Stock-Based Compensation.

Page 75: N/A

Page 76: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 77: Report of Independent Registered Public Accounting Firm

Page 78: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 79: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 80: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 81: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 82: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 83: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 84: AUXILIUM PHARMACEUTICALS, INC. AND SUBSIDIARIES

Page 85: (b) Liquidity

Page 86: (e)

Page 87: Customer concentration-

Page 88: (h) Inventories

Page 89: (m) Income Taxes

Page 90: (q) Segment Information

Page 91: (3) Fair Value Measurement

Page 92: (4) Cash, Cash Equivalents and Short-term Investments

Page 93: (5) Inventories

Page 94: (8) Collaboration and License Agreements

Page 95: (b) Asahi Kasei

Page 96: (d) FCB

Page 97: (e) Ipsen

Page 98: (9) Revolving Credit Agreement

Page 99: (b) Supply Agreements

Page 100: N/A

Page 101: (13) Common Stock and Redeemable Convertible Preferred Stock

Page 102: (b) Stock Options and Stock Awards

Page 103: (d) Stock Award Information

Page 104: (f) Valuation and Expense Information

Page 105: (16) Subsequent event

Page 106: N/A

Page 107: Evaluation of Disclosure Controls and Procedures

Page 108: Changes in Internal Control over Financial Reporting

Page 109: PART III

Page 110: PART IV

Page 111: SIGNATURES

Page 112: EXHIBIT INDEX

Page 113: N/A

Page 114: N/A

Page 115: N/A

Exhibits

Interactive Data

   CURRENT PAGE
    Download Current Page as a Word Document  Download Current Page as a PDF Document    Download Excel File of Financials